Consistent with this result, we also observed gefitinib-induced increases in phosphorylated ATM and γ-H2AX in a panel of three independently derived gefitinib-resistant, EGFR mutant NSCLC cell lines whose growth was not affected by gefitinib treatment (Fig. 1C and fig. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.